Biocon share price hits lifetime high on USFDA approval to cancer drug; stock jumps 6%
Fulphila is the first FDA-approved biosimilar to Neulasta and the second biosimilar from Mylan and Biocon’s joint portfolio approved in the US Mylan anticipates launching Fulphila in the coming weeks.
Mylan and Biocon are exclusive partners on a broad portfolio of biosimilar and insulin products. Image source: Reuters